Antimicrobial peptides: A novel and promising arsenal against methicillin-resistant Staphylococcus aureus (MRSA) infections

Despite years of research, technological advancements, and the widespread use of vaccines and antibiotics as tools to combat microbial threats to humans, methicillin-resistant Staphylococcus aureus (MRSA) infections remain a serious threat to global healthcare systems. The challenge of MRSA is a result of the bacteria's remarkably rapid evolution and adaptation, building up a collection of resistance genes that defeat the mechanism of traditional antibiotics. Conventional antibiotics, including the most notable beta-lactam antibiotics, such as penicillin and cephalosporin, are increasingly inadequate against the rapid adaptability and resistance of MRSA. Consequently, the scientific community's therapeutic arsenal for battling MRSA infections is becoming increasingly limited, necessitating innovative interventions. Antimicrobial peptides (AMPs), with their precise targeting mechanisms and innate modifiability, have emerged as promising therapeutic agents. By selectively interrupting bacterial processes and boosting innate immunological responses, AMPs offer a multifaceted strategy. Modern biotechnological and bioinformatics advancements have enabled the refinement of AMPs for improved efficacy. This comprehensive review delves into the intricate facets of MRSA pathogenicity, determinants of resistance, foundational tenets of peptide-based therapeutics, and recent scientific breakthroughs. A comprehensive analysis of the current research landscape, clinical implications, and persistent challenges underscores the potential of precisely tailored peptides as formidable weapons for counteracting the enduring threat of MRSA infections.